Gilead Licenses Hepatitis Therapy in India Amid Price Criticism
This article is for subscribers only.
Gilead Sciences Inc. licensed seven India-based generic drugmakers to bring cheaper versions of Sovaldi to 91 countries, expanding the reach of a hepatitis C drug that is sold for $84,000 in the U.S.
The agreements allow Cadila Healthcare Ltd., Cipla Ltd., Hetero Labs Ltd., Mylan Laboratories Ltd., Ranbaxy Laboratories Ltd., Sequent Scientific Ltd. and Strides Arcolab Ltd. to make Sovaldi, Gilead said in a statement.